Anti CD34 monoclonal antibody/sirolimus - OrbusNeich

Drug Profile

Anti CD34 monoclonal antibody/sirolimus - OrbusNeich

Alternative Names: Combo Dual Therapy Stent; COMBO Plus Dual Therapy Stent; OrbusNeich Combo Stent™

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OrbusNeich
  • Class Anti-infectives; Ischaemic heart disorder therapies; Macrolides; Monoclonal antibodies
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • No development reported Coronary artery disease

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Coronary artery disease in China (Intracoronary, Implant)
  • 30 Oct 2017 Efficacy data from the phase II/III Japan-USA HARMONEE registrational trial in Coronary artery restenosis released by OrbusNeich
  • 05 Aug 2015 Phase-II development is ongoing for Coronary restenosis (prevention) in Australia and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top